BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

DBT announces COVID-19 research consortium

25 March 2020 | News

Urgent need to develop safe and effective countermeasures that can be available



To support the preparedness, readiness and response for COVID-19, project proposals are being solicited for developing Diagnostics, Vaccines, Novel Therapeutics, Repurposing of Drugs or any other intervention for control of COVID-19 by Industry/Academia/ Industry-Academia participation.

As part of the research consortium developed by the Department of Biotechnology (DBT), Government of India, research proposals are being called for the following areas-

Diagnostics:

To develop technologies/Assays/components for diagnosis of coronavirus and SARSCoV-2 including diagnostic methods such as ELISA, Lateral Flow assay, Molecular diagnostics (PCR, Real Time PCR), Colorimetric tests, Chemiluminescence, Immunoassays, cell culture.

Vaccines:

Vaccine technology platforms, novel vaccine manufacturing technologies, vaccine candidates and enabling disciplines for corona virus vaccine development

Type of candidate vaccine can be DNA, RNA, Live Attenuated Virus, Non-Replicating Viral Vector, Protein Subunit, Replicating Viral Vector at any stage of development

In-licensing technology for optimization, scale-up and manufacturing

Novel Therapeutics:

To develop in-vitro assay/animal models and standardize challenge studies

Screen existing libraries (Biologicals and Chemicals) and identify potential hits for development

Novel methods of B-cell isolation/ monoclonal antibody development

Repurposing of Drugs:

Develop prophylaxis clinical studies and prioritize in healthcare workers

Evaluate existing marketed drugs under a standard protocol in patients of COVID-19

Any other:

Development of any other intervention/technology related to SARS-CoV-2 outbreak prevention and contro